Table 5a Summary of previous published data on MED12 mutations in FAs and PTs
From: MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours
Publication | Number of PTs in the study | Frequency in FAs | Frequency in benign PTs | Frequency in Bo PTs | Frequency in malignant PTs | Frequency in PTs that recurred vs none recurrent cases | Evidence of temporal heterogeneity in recurrent PTs | Evidence of acquisition of mutations in recurrent PTs | Evidence of heterogeneity in synchronous PTs/FAs |
|---|---|---|---|---|---|---|---|---|---|
83 primary 14 recurrences | 70% | 58.3% | 63.3% | 27.6% | 50% vs 49% | Yes 3/6 recurrences had different MED12 mutations compared with primary tumour | No | NA | |
15 | NA | 80% | 80% | 40% | NA | NA | NA | NA | |
Lien et al (2016a) | 49 | 47.1% | 72.7% | 70.6% | 70% | NA | NA | NA | NA |
30 | NA | NA | NA | 30% | NA | NA | NA | NA | |
24 primary 2 recurrences | 47% | 80% | 67% | 0% | 50% vs 82% | No | No | Yes: 6 cases | |
11 | 67% | NA | NA | NA | NA | NA | NA | NA | |
112 primary 10 recurrences | 59% | 65.1% | 65.6% | 42.8% | Higher recurrence likelihood in those without MED12 mutations | NA | NA | NA | |
16 | 62% | 73% | NA | 20% | NA | NA | NA | NA | |
47 | 65% | 88% | 78% | 8% | NA | NA | NA | Yes: 4 cases | |
76 | NA | 80% | 64% | 23% | NA | NA | NA | NA | |
79 | 86% | 82% | 63% | 60% | NA | NA | NA | No: 1 case | |
176 number of recurrences not stated | 71.4% | 51% | 26.9% | MED12 mutations associated with a non-significant improvement in DFS | NA | NA | NA | ||
Yoshida M et al (2015) | 46 | 62% | 83% | 80% | 77% | NA | NA | NA | NA |
Current study | 75 primary 21 recurrences | 21% | 54% | 27% | 22% | 19 vs 41% | Yes | Yes | Yes |
